OrganOx Secures £25M to Innovate Transplant Solutions
Unlocking the Future of Transplant Medicine: OrganOx Secures £25M in Growth Funding
In a significant leap for the healthcare industry, OrganOx, an innovative medical device company based in Oxford, UK, has successfully raised £25M in Growth funding. This funding round, spearheaded by Lauxera Capital Partners, sets the stage for OrganOx to revolutionize liver transplants, paving the way for advancements that could change the lives of thousands. The funding will accelerate their expansion efforts, allowing the company to extend its commercial footprint and build state-of-the-art manufacturing facilities.
Founded in 2008 by esteemed Oxford University Professors Peter Friend and Constantin Coussios, OrganOx is led by CEO Craig Marshall and specializes in cutting-edge normothermic machine perfusion.
Their flagship product, the metra, utilizes proprietary NMP technology to keep donor livers in optimal condition for up to 24 hours prior to transplantation. This advancement enables medical teams to assess the organ's viability effectively, allowing for the transplantation of previously rejected organs and opening the door to lifesaving opportunities for patients in need.
Already making waves in the medical community, the metra device has played a vital role in over 2,500 liver transplants across the globe. With CE Mark approval in Europe and aspirations to expand further into the United States, OrganOx is poised to attract more investors interested in transforming healthcare. The company’s commitment to conducting extensive post-market clinical evaluations will not only enhance their product offerings but also establish them as a leader in the transplant sector, ultimately securing their place in the future of medical innovation.
Key Terms Explained
- OrganOx
- A UK-based innovative medical device company specializing in normothermic machine perfusion, specifically for keeping donor livers in optimal condition for transplantation.
- £25M in Growth funding
- A significant amount of investment secured by OrganOx to facilitate their expansion and manufacturing facilities. Growth funding is a type of investment intended to support the business expansion of a company.
- Investors
- Individuals or organizations that commit capital with the expectation of obtaining financial return. In the context of startup companies like OrganOx, investors provide the necessary capital to help the company grow in exchange for equity or potential profit.
Frequently Asked Questions
- How much funding did OrganOx secure for growth?-OrganOx successfully raised £25M in Growth funding.
- Who were the primary investors in OrganOx's recent funding round?+
- What notable product does OrganOx specialize in for transplant medicine?+
- What impact has the metra device made on the transplant medicine industry?+
- Who founded OrganOx?+
They've invested in OrganOx
Get to know these Healthtech investors
Click here for a full list of 6,908+ startup investors in the UK